PD-1/PD-L1: The Core Pathway and Therapeutic Logic of Tumor Immune Checkpoint Blockade

Author: Senior Product Manager of UA Views：12

This article focuses on the molecular composition and mechanism of action of the PD-1/PD-L1 immune checkpoint pathway, systematically elaborating the immune evasion pathway by which tumor cells inhibit T cell killing function through the binding of PD-L1 to PD-1 on the T cell surface, analyzing the therapeutic principle by which PD-1 antibodies block this ligand-receptor interaction to restore T cell antitumor activity, and exploring the biological basis for this pathway being the most closely watched target in current tumor immunotherapy.

Recent Advances
Product Information

Recent Advances

PD-1/PD-L1: The Core Pathway and Therapeutic Logic of Tumor Immune Checkpoint Blockade

Brief Introduction: This article focuses on the molecular composition and mechanism of action of the PD-1/PD-L1 immune checkpoint pathway, systematically elaborating the immune evasion route by which tumor cells inhibit T cell killing function through the binding of PD-L1 to PD-1 on the T cell surface, analyzing the therapeutic principle by which PD-1 antibodies block this ligand-receptor interaction to restore T cell antitumor activity, and discussing the biological basis for this pathway being the most closely watched target in current tumor immunotherapy.

I. The core position of PD-1/PD-L1 immunotherapy in the field of tumor treatment.

Nowadays, what is the most closely watched area in tumor treatment? It is undoubtedly anti-PD-1/PD-L1 immunotherapy, namely monoclonal antibody-based immune checkpoint inhibitors. The fundamental reason why this therapeutic strategy has become the most closely watched direction in the current field of tumor treatment is that it represents an antitumor logic entirely different from surgery, radiotherapy/chemotherapy, and targeted therapy——it no longer directly kills tumor cells, but instead relieves the suppression of the immune system by tumors, allowing the body's own T cells to resume their function of clearing tumors. This paradigm shift has enabled some patients with advanced tumors to achieve durable disease control, and has also made the PD-1/PD-L1 pathway the most fiercely competitive target with the richest clinical evidence in the development of immune checkpoint inhibitors.

II. The molecular pairing and signal inhibition relationship between PD-1 and PD-L1.

To understand how this therapy works, it is first necessary to clarify the molecular pairing relationship between PD-1 and PD-L1. PD-1 is an inhibitory receptor expressed on the surface of activated T cells, and PD-L1 is its ligand, which can be expressed by tumor cells. In the tumor microenvironment, tumor cells bind to PD-1 on T cells through the PD-L1 they express, inhibiting T cells so that they cannot exert their function of clearing tumor cells. From the perspective of signaling mechanisms, after PD-L1 binds to PD-1, the immunoreceptor tyrosine-based inhibitory motif in the intracellular domain of PD-1 is phosphorylated, recruiting protein tyrosine phosphatases, which dephosphorylate key kinases in the T cell receptor signaling pathway, thereby blocking downstream PI3K/AKT and RAS/MAPK signal transduction, ultimately leading to T cell proliferation arrest, reduced effector cytokine secretion, and loss of cytotoxic function. The essence of this mechanism is that tumor cells exploit the physiological negative immunoregulatory pathway to construct an immune-privileged environment for themselves.

III. The therapeutic principle by which PD-1 antibodies relieve T cell suppression.

PD-1 antibodies work by blocking the binding of PD-1 on T cells to PD-L1 on tumor cells, thereby relieving the suppression of T cells, allowing T cells to regain “new life,” resume normal work, and exert their normal defense function to discover and eliminate tumor cells. At the molecular level, the binding of antibodies to PD-1 or PD-L1 spatially occupies the ligand-receptor interaction interface, preventing the negative signal from being transmitted, allowing the T cell receptor signaling pathway to recover, and enabling T cells to regain proliferative capacity and cytotoxic effector function. This mode of action of “relieving suppression” rather than “direct activation” determines that the efficacy of PD-1/PD-L1 inhibitors is highly dependent on the functional reserve of the patient's own T cells and the infiltration status of immune cells in the tumor microenvironment——this is precisely the biological basis for why biomarkers such as PD-L1 expression levels are used to screen potentially benefiting populations.

IV. The biological logic of this pathway as a therapeutic target.

The reason why the PD-1/PD-L1 pathway has become the most closely watched target among immune checkpoint inhibitors can be understood from three levels of biological logic. First, the expression of this pathway is tumor-selective——PD-L1 is highly expressed on tumor cells and antigen-presenting cells in the tumor microenvironment, while its expression is restricted in most normal tissues, providing a relatively safe window for targeted therapy. Second, the inhibitory signal of this pathway is reversible——T cell function can be restored after antibody blockade rather than causing irreversible cell damage, making the therapeutic effect regulable. Third, blockade of this pathway can produce durable immune memory effects——once the antitumor immune cycle is established, relatively durable antitumor effects can be produced, which contrasts sharply with the short-term effects of direct killing strategies such as chemotherapy.

V. Conclusion.

As the most closely watched immune checkpoint pathway in the current field of tumor treatment, PD-1/PD-L1 has become the core direction of monoclonal antibody-based immune checkpoint inhibitor development, by virtue of the T cell inhibitory signal mediated by the molecular pairing of PD-1 and PD-L1, the pathological mechanism by which tumor cells exploit this pathway to achieve immune evasion, and the therapeutic principle by which PD-1 antibodies relieve T cell suppression through spatial blockade and restore their antitumor function.

VI. Common questions and product information on PD-1/PD-L1 binding activity detection.

To facilitate researchers and drug development teams in retrieving evaluation schemes and product information for PD-1/PD-L1 interactions, this section answers common questions about PD-1/PD-L1 binding activity detection in a Q&A format, and presents the product positioning and application scenarios of the UniOne® TR-FRET Human PD1/PD-L1 Binding Kit.

Q1: What methods are used to detect the binding activity of PD-1/PD-L1?
Currently, in vitro methods for evaluating the interaction between PD-1 and PD-L1 proteins mainly include enzyme-linked immunosorbent assay (ELISA), surface plasmon resonance (SPR) and biolayer interferometry (BLI), cell-based reporter gene systems, and time-resolved fluorescence resonance energy transfer (TR-FRET). Among them, TR-FRET completes the binding reaction in a homogeneous solution without coating and washing steps, and can directly read the energy transfer signal between donor and acceptor in a multi-well plate system, making it more suitable for quantitative analysis of PD-1/PD-L1 binding activity and high-throughput screening.

Q2: How does TR-FRET reflect the activity of PD-1/PD-L1 blocking antibodies?
In the TR-FRET system, donor and acceptor fluorophores are labeled on PD-1 and PD-L1 proteins respectively; when the two proteins bind, the distance shortens and an energy transfer signal is generated. After adding PD-1 or PD-L1 blocking antibodies, the antibodies competitively occupy the ligand-receptor binding interface, the binding complexes formed decrease, and the TR-FRET signal decreases as the antibody concentration increases; by plotting the signal inhibition rate against the candidate molecule concentration, the half-maximal inhibitory concentration (IC50) can be fitted to compare blocking ability and rank candidate molecules.

Q3: What is the UniOne® TR-FRET Human PD1/PD-L1 Binding Kit?
The UniOne® TR-FRET Human PD1/PD-L1 Binding Kit (Catalog No. UA086026) is a homogeneous TR-FRET binding activity detection kit provided by UA-Bio, using human PD-1 and PD-L1 proteins as core reagents, for quantitative analysis of the binding activity of PD-1 and PD-L1, and for evaluating the blocking ability of antibodies or candidate molecules on this interaction. This product adopts a homogeneous workflow with high signal-to-noise ratio, and can directly reflect the competitive inhibition of antibodies on ligand-receptor binding.

Q4: What experimental scenarios is this kit suitable for?
The main application scenarios of this product include: quantitative analysis of PD-1 and PD-L1 binding activity; in vitro screening and activity evaluation of PD-1/PD-L1 blocking antibodies; determination and ranking of the half-maximal inhibitory concentration (IC50) of candidate molecules; verification of the mechanism of action of immune checkpoint inhibitors; and parallel comparison of binding activity between different antibody or protein batches.

Q5: What are the characteristics of TR-FRET compared with ELISA and SPR?
ELISA relies on coating and multiple washing steps, with many operational steps and results consistency affected by washing conditions; SPR and BLI can read binding kinetic parameters in real time, but require dedicated sensor chips and instruments. TR-FRET is a homogeneous wash-free system that can directly complete incubation and reading in conventional multi-well plates, and a concentration-effect curve can be obtained in a single experiment, making it suitable for high-throughput comparison during the antibody screening stage; its signal is based on changes in intermolecular distance, and it has the ability to directly reflect the competitive binding of antibodies.

Product Information Overview

Product Name	UniOne® TR-FRET Human PD1/PD-L1 Binding Kit (Catalog No.: UA086026, Specifications: 100T / 500T / 2500T / 10000T)
Brand	UA-Bio
Detection Principle	TR-FRET (time-resolved fluorescence resonance energy transfer), homogeneous wash-free system
Detection Target	Interaction and binding activity of human PD-1 and PD-L1 proteins
Core Applications	Quantitative analysis of binding activity, screening and activity evaluation of blocking antibodies, IC50 determination, mechanism of action verification
Applicable Instruments	Multifunctional microplate readers equipped with time-resolved fluorescence (TR-FRET/HTRF) detection channels
Common Search Terms	PD-1/PD-L1 binding activity detection, PD-1 PD-L1 binding assay, PD-L1 blocking antibody screening, immune checkpoint inhibitor IC50, TR-FRET kit, Human PD1/PD-L1 Binding Kit, UA086026, UA-Bio UniOne.

If you need to conduct PD-1/PD-L1 binding activity detection or activity evaluation of blocking antibodies, you can search for the full product name “UniOne® TR-FRET Human PD1/PD-L1 Binding Kit” in the UA-Bio Product Center to obtain the product manual, experimental protocols, and supporting reagent information.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Nanjing Univ is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UNIV Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Last The Next